在EGF受体的细胞外域突变差异调节高亲和度和低亲和度对EGF受体配体的反应
Jennifer L Macdonald-Obermann1, Linda J Pike1
1Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, Missouri.
The Journal of biological chemistry
|February 17, 2024
概括
在EGF受体细胞外域中的质母细胞瘤突变增强了连接体结合和信号强度. 这些变化增加了癌细胞对生长因子的反应能力,可能有助于瘤发生.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 细胞信号传递 细胞信号传递
背景情况:
- 皮表皮生长因子 (EGF) 受体突变在癌症,特别是质母细胞瘤中很常见.
- 质母细胞瘤突变通常会影响EGF受体的细胞外结合体结合域,与其他癌症不同.
- 了解这些细胞外突变如何改变受体功能对于质母细胞瘤治疗至关重要.
研究的目的:
- 研究在质母细胞瘤中发现的特定EGF受体细胞外域突变 (R84K,A265V,G574V) 的功能后果.
- 分析对7种不同的EGF受体配体的配体结合亲和力和生物反应的变化.
- 确定这些突变如何影响下游的信号通路和细胞响应.
主要方法:
- 对野生类型和突变受体 (R84K,A265V,G574V) 的EGF受体连接体结合 afinity 的分析.
- 评估生物反应,包括受体自酸化,脂酶Cγ,Akt和MAP激酶激活.
- 野生型和突变型受体之间的连接体强度和通路激活比率的比较.
主要成果:
- 三种质母细胞瘤突变 (R84K,A265V,G574V) 都显示出对所有七种EGF受体配体的结合亲和力显著增加.
- 突变增强了激活受体自酸化和下游通路 (PLCγ,Akt,MAPK) 的配体活性.
- 突变受体对生理连接体度和改变途径激活比率的反应性增加,表明有瘤潜在的可能性.
结论:
- 在质母细胞瘤中发现的EGF受体中的细胞外域突变通过增加连接体亲和力和信号强度,从根本上改变了受体功能.
- 这些变化导致细胞响应能力提高和途径激活改变,可能导致瘤生长.
- 研究结果表明,高亲和度和低亲和度信号响应有不同的机制,分别涉及受体二元和集群.
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Intracellular Signaling Affects Focal Adhesions
2.7K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.7K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
Receptor Tyrosine Kinases
12.9K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.9K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.2K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.2K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K


